Samsung Biologics Co.,Ltd. 207940.KS

Healthcare · Biotechnology · valued as of 2026-11-03 · statements 2025-12-31

Average Intrinsic Value
$17.06B
Market Cap
$51.61B
Margin of Safety
-202.5%
Intrinsic / Market Ratio
0.33

How Each Value Is Built

The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.

EPV + Growth

16.58B USD

what the normal year's earnings are worth for ever, plus growth that pays

Profit

18.26B USD

15 years of cash the shareholders can take out, and the equity left at year 15

FCFF

16.34B USD

15 years of cash for shareholders and lenders, less what is owed

Intrinsic Value

17.06B USD

the plain average of the three, uncapped, as the screener averages them

Intrinsic Value

17.06B USD

from the sum above

Market Cap

51.61B USD

today's price times the shares

Intrinsic Value ÷ Market Cap

0.33×

the ratio the screener ranks by; Margin of Safety -202.5% (1 − Market Cap ÷ Intrinsic Value)

Each card below builds one of the three values from the reported years.

Earnings power value plus growth: 16.58B USD
What the normal year's operating profit after tax is worth if it lasts for ever, plus what the new investment adds beyond its cost, less the net debt that comes before the shareholders (or plus the net cash).
①EPV (earnings power value)15.95B USD
+②Net Cash Today630.87M USD
+③Growth Value0 USD
=Value16.58B USD

EPV of the Operations (NOPAT over WACC)

15.95B USD

Net cash today

+630.87M USD

Growth Value

0 USD

Value

16.58B USD

①EPV (earnings power value)

15.95B USD

②Net Cash Today

630.87M USD

③Growth Value

0 USD

Market value

Market Cap51.61B USD

Today's price times the shares.

Value vs market

Margin of Safety-211.3%

1 minus the market cap as a share of the value.

Profit value: today's value of the shareholders' equity, from the cash it can pay them (FCFE): 18.26B USD
Fifteen years of free cash flow to equity (FCFE), each brought to today at the cost of equity, plus the equity at year 15 brought to today.
①Present Value of the 15 Years of FCFE7.73B USD
+②Equity at Year 15, Today10.53B USD
=Value18.26B USD
FCFE: the net income left for the shareholders once the business keeps what next year's growth needsEquity reinvestment: the part of the year's net income kept in the business to grow the next year; below zero, capital the business releases to the shareholdersPresent value of the FCFEColoured bars show the FCFE, grey bars the equity reinvestment. With a positive equity reinvestment the two stacked are the year's normalized income; with a negative one the grey is below zero, capital the business releases, and the normalized income is the FCFE plus that negative amount. Shaded, years 6 to 10: the growth falling to its long-run rate and the ROE on new investment falling to the cost of equity. Axes linear.

①Present Value of the 15 Years of FCFE

7.73B USD

②Equity at Year 15, Today

10.53B USD

Market value

Market Cap51.61B USD

Today's price times the shares.

Value vs market

Margin of Safety-182.6%

1 minus the market cap as a share of the value.

FCFF value: today's value of the shareholders' equity, from the cash the firm can pay its shareholders and lenders (FCFF): 16.34B USD
Fifteen years of free cash flow to the firm (FCFF), each brought to today at the WACC, plus the invested capital at year 15 brought to today, less the net debt today (or plus the net cash).
①Present Value of the 15 Years of FCFF8.53B USD
+②Invested Capital at Year 15, Today7.18B USD
+③Net Cash Today630.87M USD
=Value16.34B USD
FCFF: the NOPAT left for the shareholders and the lenders once the business reinvests what next year's growth needsReinvestment: the part of the year's NOPAT put back into the business to grow the next year; below zero, capital the business releasesPresent value of the FCFFColoured bars show the FCFF, grey bars the reinvestment. With a positive reinvestment the two stacked are the year's NOPAT; with a negative one the grey is below zero, capital the business releases, and the NOPAT is the FCFF plus that negative amount. Shaded, years 6 to 10: the growth falling to its long-run rate and the ROIC on new investment falling to the WACC. Axes linear.

①Present Value of the 15 Years of FCFF

8.53B USD

②Invested Capital at Year 15, Today

7.18B USD

③Net Cash Today

630.87M USD

Market value

Market Cap51.61B USD

Today's price times the shares.

Value vs market

Margin of Safety-215.9%

1 minus the market cap as a share of the value.

The Rates and the Capital the Values Read

The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.

WACC: 5.58%
weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.
Cost of Equity =Risk-Free Rate 4.50%+Beta 0.19×Market Risk Premium 6.00%= 5.63%

The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.

Tax Rate for WACC =Tax Provision 351.07M USDPretax Income 1.47B USD= 23.80%

The tax the interest saves.

Interest Expense =EBIT 1.50B USD−Pretax Income 1.47B USD= 20.31M USD

The interest the company paid: EBIT is the profit before tax plus the interest.

Cost of Debt =Interest Expense 20.31M USDTotal Debt 805.92M USD×(1 − Tax Rate for WACC 23.80%)= 1.92%

What the lenders are paid a year after the tax the interest saves.

Debt Weight =Total Debt 805.92M USDMarket Cap + Total Debt 51.61B USD + 805.92M USD= 1.54%

The part of the capital the lenders put in, at market value.

WACC =Equity Weight 98.46%×Cost of Equity 5.63%+Debt Weight 1.54%×Cost of Debt 1.92%= 5.58%

Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.

Book value and net debt today
Both from the balance sheet of the newest quarter, 2026-06-30.

Total Assets 8.21B USD − Total Liabilities 2.79B USD = Book Value Today 5.43B USD

Total Debt 805.92M USD − Cash and Short-Term Investments 1.44B USD = Net Debt Today -630.87M USD

The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.

Quality metrics
Read beside the value, never a condition for it: every company is valued, and a filter in the list is the reader's choice.
MetricFrom
Share dilutionShares Today ÷ Shares Two Years Back − 1-35.0%at most 5%passes46,239,518 / 71,174,000
Accrual quality(Operating Cash Flow − Net Income) ÷ Total Assets3.9%at least -10.0%passes(1.56B USD − 1.24B USD) ÷ 8.21B USD
Price to bookMarket Cap ÷ Book Value Today9.51×at most 3×does not pass51.61B USD ÷ 5.43B USD
Operating marginOperating Income ÷ Revenue45.4%above 10.0%passes1.44B USD ÷ 3.17B USD
Revenue growthRevenue ÷ Revenue a Year Before − 133.0%above 10.0%passes3.17B USD / 2.39B USD
Net cash(Cash − Total Debt) ÷ Market Cap-1.2%above -30%passes(187.36M USD − 805.92M USD) ÷ 51.61B USD
Operating efficiencyOperating Income ÷ Gross Profit82.2%above 25.0%passes1.44B USD ÷ 1.75B USD

Market Data

The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.

Market data
The data provider's own ratios and the analysts' consensus, read beside the valuation, never in it.

Share price

1.47M USD

Enterprise value

62.02T USD

market cap plus net debt

EV / EBITDA

21.91×

Price / book

—

the provider's book

Price / earnings

—

Return on equity

18.5%

the provider's, not the engine's

Profit margin

38.8%

Revenue growth

30.2%

Analyst target, mean

1.88M USD

Analysts

27

opinions in the consensus

Financial Statements

The income statement, the balance sheet and the cash flow the screener holds, year by year, in USD.

Financial statements, year by year
The annual lines the screener holds today, in USD at each period's rate; the figures this valuation read are in its calculation above.
USD2022202320242025
Income statement

Revenue

2.38B2.89B2.39B3.17B

Gross profit

1.17B1.41B1.17B1.75B

Operating income

781.28M872.40M901.39M1.44B

EBITDA

operating income before depreciation and amortisation

1.10B1.32B1.38B1.94B

Pretax income

801.45M877.35M944.71M1.47B

Net income

633.88M671.88M739.00M1.24B

Normalized income

net income without one-off items, as the data provider prints it; Profit's line when printed

588.16M673.44M712.21M1.13B

R&D

36.44M63.91M25.04M25.88M
Balance sheet, year end

Total assets

13.17B12.57B11.83B7.70B

Total liabilities

6.03B4.87B4.39B2.51B

Shareholders' equity

the equity the parent's shareholders own, as printed, without minority interest; the book value the values read is total assets less total liabilities, in Book Value and Net Debt above

7.14B7.70B7.44B5.19B

Total debt

2.00B1.50B1.01B645.40M

Cash and equivalents

707.56M288.22M266.88M103.62M

Net PP&E

fixed assets after depreciation

3.08B3.40B3.98B4.20B

Working capital

current assets less current liabilities

1.81B1.07B1.14B1.31B
Cash flow

Operating cash flow

756.99M1.31B1.13B1.56B

Capital expenditure

paid out, so below zero

-801.61M-865.86M-939.70M-1.03B

Depreciation and amortisation

244.85M383.67M408.68M441.11M

Free cash flow

operating cash flow plus capital expenditure

-44.62M439.39M192.19M537.94M